Literature DB >> 28218259

Approvals in 2016: questioning the clinical benefit of anticancer therapies.

Christopher M Booth1, Joseph C Del Paggio2.   

Abstract

Mesh:

Substances:

Year:  2017        PMID: 28218259     DOI: 10.1038/nrclinonc.2017.18

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

1.  Progression-free survival: meaningful or simply measurable?

Authors:  Christopher M Booth; Elizabeth A Eisenhauer
Journal:  J Clin Oncol       Date:  2012-02-27       Impact factor: 44.544

Review 2.  Reflections on medical oncology: 25 years of clinical trials--where have we come and where are we going?

Authors:  Christopher M Booth; Ian Tannock
Journal:  J Clin Oncol       Date:  2008-01-01       Impact factor: 44.544

3.  Progress in cancer care: the hope, the hype, and the gap between reality and perception.

Authors:  Leonard B Saltz
Journal:  J Clin Oncol       Date:  2008-09-15       Impact factor: 44.544

4.  Absolute benefits of medical therapies in phase III clinical trials for breast and colorectal cancer.

Authors:  B Seruga; P C Hertz; L Wang; C M Booth; D W Cescon; M Krzyzanowska; I F Tannock
Journal:  Ann Oncol       Date:  2009-11-30       Impact factor: 32.976

5.  A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).

Authors:  N I Cherny; R Sullivan; U Dafni; J M Kerst; A Sobrero; C Zielinski; E G E de Vries; M J Piccart
Journal:  Ann Oncol       Date:  2015-05-30       Impact factor: 32.976

6.  Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received.

Authors:  Lowell E Schnipper; Nancy E Davidson; Dana S Wollins; Douglas W Blayney; Adam P Dicker; Patricia A Ganz; J Russell Hoverman; Robert Langdon; Gary H Lyman; Neal J Meropol; Therese Mulvey; Lee Newcomer; Jeffrey Peppercorn; Blase Polite; Derek Raghavan; Gregory Rossi; Leonard Saltz; Deborah Schrag; Thomas J Smith; Peter P Yu; Clifford A Hudis; Julie M Vose; Richard L Schilsky
Journal:  J Clin Oncol       Date:  2016-05-31       Impact factor: 44.544

7.  Do Contemporary Randomized Controlled Trials Meet ESMO Thresholds for Meaningful Clinical Benefit?

Authors:  J C Del Paggio; B Azariah; R Sullivan; W M Hopman; F V James; S Roshni; I F Tannock; C M Booth
Journal:  Ann Oncol       Date:  2017-01-01       Impact factor: 32.976

8.  Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

Authors:  Martin Schlumberger; Makoto Tahara; Lori J Wirth; Bruce Robinson; Marcia S Brose; Rossella Elisei; Mouhammed Amir Habra; Kate Newbold; Manisha H Shah; Ana O Hoff; Andrew G Gianoukakis; Naomi Kiyota; Matthew H Taylor; Sung-Bae Kim; Monika K Krzyzanowska; Corina E Dutcus; Begoña de las Heras; Junming Zhu; Steven I Sherman
Journal:  N Engl J Med       Date:  2015-02-12       Impact factor: 91.245

9.  Evolution of the randomized controlled trial in oncology over three decades.

Authors:  Christopher M Booth; David W Cescon; Lisa Wang; Ian F Tannock; Monika K Krzyzanowska
Journal:  J Clin Oncol       Date:  2008-10-27       Impact factor: 44.544

10.  Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.

Authors:  William D Tap; Robin L Jones; Brian A Van Tine; Bartosz Chmielowski; Anthony D Elias; Douglas Adkins; Mark Agulnik; Matthew M Cooney; Michael B Livingston; Gregory Pennock; Meera R Hameed; Gaurav D Shah; Amy Qin; Ashwin Shahir; Damien M Cronier; Robert Ilaria; Ilaria Conti; Jan Cosaert; Gary K Schwartz
Journal:  Lancet       Date:  2016-06-09       Impact factor: 79.321

  10 in total
  13 in total

1.  Patent trend and competitive analysis of cancer immunotherapy in the United States.

Authors:  Chia-Lin Pan; Feng-Chi Chen
Journal:  Hum Vaccin Immunother       Date:  2017-11-02       Impact factor: 3.452

Review 2.  Predictive validity in drug discovery: what it is, why it matters and how to improve it.

Authors:  Jack W Scannell; James Bosley; John A Hickman; Gerard R Dawson; Hubert Truebel; Guilherme S Ferreira; Duncan Richards; J Mark Treherne
Journal:  Nat Rev Drug Discov       Date:  2022-10-04       Impact factor: 112.288

Review 3.  Patient-reported outcomes in cancer care - hearing the patient voice at greater volume.

Authors:  Thomas W LeBlanc; Amy P Abernethy
Journal:  Nat Rev Clin Oncol       Date:  2017-10-04       Impact factor: 66.675

4.  Targeting the value of targeted therapy.

Authors:  Joseph C Del Paggio; Richard Sullivan; Christopher M Booth
Journal:  Oncotarget       Date:  2017-10-07

Review 5.  The Making of Leukemia.

Authors:  Inés González-Herrero; Guillermo Rodríguez-Hernández; Andrea Luengas-Martínez; Marta Isidro-Hernández; Rafael Jiménez; Maria Begoña García-Cenador; Francisco Javier García-Criado; Isidro Sánchez-García; Carolina Vicente-Dueñas
Journal:  Int J Mol Sci       Date:  2018-05-17       Impact factor: 5.923

6.  The Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: Rationale and design of the database and the collection of evidence available at approval of novel drugs.

Authors:  Aviv Ladanie; Benjamin Speich; Florian Naudet; Arnav Agarwal; Tiago V Pereira; Francesco Sclafani; Juan Martin-Liberal; Thomas Schmid; Hannah Ewald; John P A Ioannidis; Heiner C Bucher; Benjamin Kasenda; Lars G Hemkens
Journal:  Trials       Date:  2018-09-19       Impact factor: 2.279

7.  Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.

Authors:  Courtney Davis; Huseyin Naci; Evrim Gurpinar; Elita Poplavska; Ashlyn Pinto; Ajay Aggarwal
Journal:  BMJ       Date:  2017-10-04

8.  Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe.

Authors:  Rick A Vreman; Huseyin Naci; Wim G Goettsch; Aukje K Mantel-Teeuwisse; Sebastian G Schneeweiss; Hubert G M Leufkens; Aaron S Kesselheim
Journal:  Clin Pharmacol Ther       Date:  2020-04-20       Impact factor: 6.875

Review 9.  Facing the Global Challenges of Access to Cancer Medication.

Authors:  Abdul Raman Jazieh; Abdulaziz H Al-Saggabi; Mark McClung; Robert Carlson; Lowell E Schnipper; Alexandru Eniu; Barri Blauvelt; Yousuf Zafar; David Kerr
Journal:  J Glob Oncol       Date:  2018-09

10.  Characteristics of Single Pivotal Trials Supporting Regulatory Approvals of Novel Non-orphan, Non-oncology Drugs in the European Union and United States from 2012-2016.

Authors:  Anne Vinther Morant; Vivien Jagalski; Henrik Tang Vestergaard
Journal:  Clin Transl Sci       Date:  2019-03-02       Impact factor: 4.689

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.